SG Americas Securities LLC Purchases 26,764 Shares of Vericel Corporation $VCEL

SG Americas Securities LLC raised its holdings in shares of Vericel Corporation (NASDAQ:VCEL) by 290.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,983 shares of the biotechnology company’s stock after acquiring an additional 26,764 shares during the quarter. SG Americas Securities LLC’s holdings in Vericel were worth $1,132,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the business. Russell Investments Group Ltd. boosted its position in shares of Vericel by 38.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 118,856 shares of the biotechnology company’s stock valued at $5,057,000 after acquiring an additional 32,976 shares during the last quarter. Frontier Capital Management Co. LLC raised its stake in Vericel by 74.3% during the second quarter. Frontier Capital Management Co. LLC now owns 398,960 shares of the biotechnology company’s stock valued at $16,976,000 after purchasing an additional 170,006 shares in the last quarter. Strs Ohio bought a new position in Vericel during the first quarter valued at $812,000. Voya Investment Management LLC grew its stake in shares of Vericel by 68.7% in the 1st quarter. Voya Investment Management LLC now owns 24,664 shares of the biotechnology company’s stock worth $1,101,000 after buying an additional 10,048 shares in the last quarter. Finally, Congress Asset Management Co. increased its holdings in shares of Vericel by 18.0% in the 2nd quarter. Congress Asset Management Co. now owns 1,742,324 shares of the biotechnology company’s stock worth $74,136,000 after buying an additional 265,606 shares during the last quarter.

Wall Street Analyst Weigh In

VCEL has been the subject of a number of analyst reports. Wall Street Zen downgraded shares of Vericel from a “buy” rating to a “hold” rating in a report on Saturday. Zacks Research downgraded Vericel from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 12th. Truist Financial lowered their price target on Vericel from $50.00 to $45.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Vericel in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Vericel has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Vericel Stock Down 3.0%

Shares of Vericel stock opened at $37.40 on Friday. The stock’s fifty day moving average is $38.09 and its two-hundred day moving average is $36.49. The company has a market capitalization of $1.89 billion, a PE ratio of 155.84 and a beta of 1.17. Vericel Corporation has a 52 week low of $29.24 and a 52 week high of $63.00.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Thursday, November 6th. The biotechnology company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.12. The company had revenue of $67.50 million for the quarter, compared to the consensus estimate of $64.57 million. Vericel had a net margin of 5.06% and a return on equity of 4.30%. The firm’s revenue was up 16.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.02) EPS. As a group, research analysts anticipate that Vericel Corporation will post 0.14 earnings per share for the current year.

About Vericel

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.